Efficacy studies

Approval of New Drugs when Human Efficacy Studies are not Ethical or Feasible... 

In general, for smokers with cardiac disease, the benefits of nicotine replacement therapy outweigh the potential risks. In a safety and efficacy study that included veterans with cardiac disease, smoking concurrently with the nicotine patch was not associated with an increase in adverse events (Joseph et al. 1996). Although bupropion SR is generally well tolerated by smokers, it has not been adequately studied in persons with cardiac disease, and definitive conclusions regarding its safety in this patient population cannot currently be made (Society for Research on Nicotine and Tobacco 2003). 

Toxicology studies must be performed in at least two animal species. If the toxicity profile of the compound is acceptable, then it joins the hit or lead list of compounds to proceed. The metabolism of the compound must be understood and pharmacokinetic studies must be performed in small and large animals. Efficacy studies must be performed in relevant animal models, especially in chimpanzees when more than one candidate is identified and a choice has to be made before proceeding to studies in humans. The ultimate preclinical steps include various studies testing drug combinations in vitro and in vivo, selection of resistant viruses, viral fitness, pyrophosphorolysis, and others. 

Pegaptanib 0.3 mg is administered as an intravitreous injection every 6 weeks. In clinical studies, patients treated with pegaptanib experienced a slower rate of visual decline than patients treated with a sham injection.28 Vision loss continued to occur in patients and the drug was less effective in the second year of treatment. Long-term efficacy studies are not available yet.27... 

The study termination form data may be used for efficacy or safety analysis purposes. With regard to safety, if patients discontinue a study medication earlier than patients on standard therapy or placebo, then that is important to know. For efficacy analyses, patients who withdraw due to a lack of efficacy or adverse event may be precluded from being considered a treatment responder or success. Also, often the study termination date is used as a censor date in time-to-event analyses for therapy efficacy. Study termination forms play a key role in patient disposition summaries found at the start of a clinical study report. From a CDISC perspective, the study termination form is a finding. 

Drug Efficacy Study A Report to the Commissioner of Food and Drugs, National Academy of Sciences, National Research Council, Washington, DC, 1969. 

Specific adverse effects of rimonabant have not yet been released to the public, although the company that makes the drug reports that their incidence is low. Pending the completion of more safety and efficacy studies, rimonabant is expected to be available in the United States in the next couple of years. This drug may prove to be especially ideal for obese individuals who smoke, since it should help with both problems. 

FDA becomes part of the Public Health Service (PHS). The Drug Efficacy Study Implementation (DESI) is FDA s response to the investigation on the effectiveness of drugs. 

Study Design Treatment, randomized, double-blind, placebo control, parallel assignment, efficacy study... 

Study Design Treatment, randomized, open label, active control, parallel assignment, safety/efficacy study Official Title A Phase III, Randomized, Open-Label Study of Lopina-vir/Ritonavir Tablets 800/200mg Once-Daily Versus 400/100mg Twice-Daily When Co-administered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced, HIV-1 Infected Subjects Primary Outcome Measures ... 

Phase II—Safety and efficacy studies, 50-500 subjects, randomized, double-blinded... 

Kleinberg, L, Grossman, S.A., Carson, K., Lesser, G., O Neill, A., Pearlman, J., Phillips, P., Herman, T., and Gerber, M. Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy results of a phase 11 new approaches to brain tumor therapy CNS consortium safety and efficacy study. J. Clin. Oncol. 2002, 20, 3149-3155. 

Those seeking to market a generic version of an existing post-1962 brand-name drug also had to perform their own safety and efficacy studies, much like the brand-name companies had to demonstrate the safety and efficacy of the brand-name dmg. The FDA did not have a streamlined... 

Choice Efficacy Studies with 0.005% Bromethalin Bait... 

---